Developing PCR-based and serological tests for the novel coronavirus (SARS- CoV-2)
Biotechnology will change life in the 21th century at least as radically as information technology did in the 20th century. In medical applications and robotics, computer science and microelectronics will enable new analytical methods that considerably increase efficiency in areas such as pharmaceutical research, diagnosis and ultimately: Patient care.
These new methods will change the equipment used in pharmaceutical labs in the same extent as PCs changed the world of computing two decades ago: Everything used in the lab will become smaller, faster and more affordable.
Leveraging its know-how in producing micro-scale chip structures at the highest quality in large numbers, CAMPTON Diagnostics™ would like to become a driving force in this development.
Leading Scientists at the Fraunhofer Institute for Silicon Technology (ISIT), located in Germany, have developed a new Point-of-Care (POC) technology to identify cancer, infectious and autoimmune diseases in specialized medical practices or hospitals and clinics worldwide.
Selected examples of diseases which can be diagnosed using the CAMPTON Biochip System™ are:
POC diagnostics are decentralized, near patient tests usually performed through the use of portable devices. The use of these tests can provide faster results, helping to improve patient care and treatment.
This system solution will be certified, produced and sold on a worldwide basis by the newly founded company CAMPTON Diagnostics™, which is located in Germany.
The relevant technology is patented by Fraunhofer and licensed by CAMPTON Diagnostics™.